A retrospective evaluation of patients with recurrent aphthous stomatitis Rekürren aftöz stomatitli hastaların retrospektif olarak değerlendirilmesi


Topaloğlu Demir F., Demir M., TÜRKOĞLU Z., DİZEN NAMDAR N.

Haseki Tip Bulteni, cilt.55, sa.1, ss.7-14, 2017 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/haseki.3231
  • Dergi Adı: Haseki Tip Bulteni
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.7-14
  • Anahtar Kelimeler: Aphthous stomatitis, oral ulcer, Behcet's disease
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Aim: To determine the factors in the etiology of recurrent aphthous stomatitis (RAS) and to evaluate patients in the terms of RAS associated systemic disorders especially Behçet’s disease. Methods: Patients with RAS, who were followed up in Bartın State Hospital Dermatology Clinic between July 2013 and April 2015, were retrospectively evaluated. Results: A total of 123 patients (86 female, 37 male) were included in this study. Thirteen (106%) patients were children. The mean age of patients was 34.5±14.7 years (range: 8-69 years). Minor aphthous somatitis was the most frequent clinical type (68.3%). Family history was positive in 52.8% of patients. The triggering factors in the etiology of RAS were stress (54.5%), trauma (40.2%), gingivitis (29.3%), food (9.8%), medicines (5.7%), menstruation in female patients (3.3%), and throat infections (2.4%). Nutritional deficiencies were found in 39% of patients. There was a statistically significant difference in attack frequency (p=0.017) and throat infection history (p=0.029) between adults and pediatric patients. Fourteen (11.4%) patients were diagnosed with Behçet’s disease. When we compared the RAS patients diagnosed with Behçet’s disease and the other RAS patients, a significant difference was found in pathergy test (p<0.001) and ferritin levels (p=0.020). Conclusion: Patients with RAS should be followed up for a long time for systemic disorders, especially for Behçet’s disease, accompanying RAS.